Velo3D's EBITDA Breakeven Pushed to H2 2026 Amid Severe Margin Deterioration and Revenue Decline

What happened

Velo3D reported Q4 2025 revenue of $9.4 million, down 25% year-over-year, with GAAP gross margin plunging to -74% due to a $7 million inventory write-off, highlighting persistent operational inefficiencies. Management's guidance now delays EBITDA breakeven to the second half of 2026, while maintaining a target of 30% gross margin and $65 million in revenue for 2026, but this revision extends an already ambitious timeline. The DeepValue master report had previously underscored the company's fragile state, with Q3 2025 gross margin at just 3.2% and going-concern warnings, indicating that the defense-led turnaround was speculative. This latest setback confirms the report's skepticism, as margin pressures and revenue volatility undermine the path to profitability. Consequently, investor skepticism has intensified, reflecting heightened concerns over execution risk and the likelihood of further dilutive capital raises.

Implication

Velo3D's extended timeline to EBITDA breakeven weakens the investment thesis that already discounted a near-term turnaround, increasing the probability of the bear case scenario from the DeepValue report. The severe gross margin deterioration, even after adjusting for one-time items, points to deeper structural challenges in scaling Rapid Production Solutions (RPS) and managing supply chain costs. With continued cash burn and tight liquidity, as highlighted in the report, the company may soon require more equity issuance, potentially diluting shareholders and capping per-share upside. Investors should reweight scenarios towards the downside, where delays and high costs persist, reducing the implied value closer to $7. Until clear evidence of margin recovery and backlog conversion emerges, existing holders might consider trimming, while prospective buyers should await lower prices or stronger operational catalysts.

Thesis delta

The investment thesis weakens significantly as the delay in EBITDA breakeven validates the DeepValue report's caution about management's aggressive targets, pushing the expected profitability timeline further out. This increases reliance on external financing and raises the risk of dilution, shifting probability weight from the base case toward the bear case. Consequently, the stock's current valuation appears less justified without immediate improvements in gross margins and defense contract execution.